Screener
Enliven Therapeutics ELVN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (97) | (69) |
| Accounts payable | (519) | 220 |
| Accrued expenses and other liabilities | (4,465) | (2,495) |
| Net cash used in operating activities | (19,291) | (24,127) |
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 108,363 | 60,672 |
| Purchases of marketable securities | (65,837) | (59,225) |
| Purchases of property and equipment | — | (20) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's operating cash flow?
- Enliven Therapeutics (ELVN) reported operating cash flow of -$19.29M in Q1 2026.
- How has Enliven Therapeutics's operating cash flow changed year-over-year?
- Enliven Therapeutics's operating cash flow increased by 20.0% year-over-year, from -$24.13M to -$19.29M.
- What is the long-term trend for Enliven Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Enliven Therapeutics's operating cash flow has grown at a 10.7% compound annual growth rate (CAGR), from -$46.77M to -$70.3M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Enliven Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude